Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.

The University of Kent has published final results for the Primary Endpoint from the now completed double-blind, placebo-controlled, randomized trial.

The study now completed is an independent, investigator initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England.

"The final analysis of the completed is still ongoing, but data for the primary endpoint, namely the duration of URTI infection are now final. The findings are really exciting as they show statistically significant reduction in episode duration. The reduction was around 50%, meaning the athletes in the ColdZyme group recovered from the infection, and would be able to return to full training, in about half the time of the placebo group (approximately 6 days vs 11 days). Analysis of the secondary endpoints, including symptom ratings and viral load reduction, is still ongoing with expected results in the coming weeks,” says professor Glen Davison.

“The now completed Gold Standard study had 164 participants enrolled and we are confidently awaiting the results for the secondary endpoints,” says Claus Egstrand, CEO of Enzymatica.

See official data from ISRCTN Registry on BCM (part of Springer Nature Group): Link

https://www.isrctn.com/ISRCTN18133939

Facts ColdZyme®  

ColdZyme® directly forms a physical barrier in the mouth and throat that coats, moisturizes and protects the oral cavity and throat, trapping viruses and inactivating and inhibiting the ability of trapped viruses to infect cells and reproduce. The over-the-counter mouth spray has been certified according to the EU regulation MDR (class III) by Eurofins, an approved European control body for medical devices. The certification entails stricter requirements for the evidence of clinical validity, safe design and market surveillance. ColdZyme® products are now MDR certified with the following expanded intended uses:

• Treat and relieve cold and flu-like symptoms.

and with the following extended product claims:

• Protects against viruses that cause cold and flu-like infections in the upper respiratory tract.

• Shortens the duration of cold and flu-like infections of the upper respiratory tract if used at an early stage of the infection.

• Relieves cold and flu-like symptoms, including sore throats.

Read more at www.ColdZyme.se

The information in the press release is such that Enzymatica is obliged to make public according to the EU's market abuse regulation. The information was submitted, through the contact person below, for publication on 16 August 2024, at 15:30 CET.